Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Dec 29, 2021 | 2021

Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvals No serious adverse events and safety concerns reported to date in the Phase 3 clinical trial...

Update – Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

by rvvadmin | Dec 3, 2021 | 2021

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3...

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

by rvvadmin | Nov 23, 2021 | 2021

TORONTO, Nov. 23, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

by rvvadmin | Nov 16, 2021 | 2021

TORONTO, Nov. 16, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

by rvvadmin | Nov 3, 2021 | 2021

Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Oct 26, 2021 | 2021

DSMB support in continuing the Phase 3 clinical trial; No serious adverse events and safety concerns reported to date. Phase 3 clinical trial to incorporate viral load testing for a minimum of 300 patients. Finalizing key research of thiol-based drugs, including...